Extracorporeal Cellular Therapy (ELAD) in Severe Alcoholic Hepatitis: A Multinational, Prospective, Controlled, Randomized Trial

Authors

Julie Thompson
Natasha Jones
Ali Al-Khafaji
Shahid Malik
David Reich
Santiago Munoz
Ross MacNicholas
Tarek Hassanein
Lewis Teperman
David Wolf, New York Medical CollegeFollow
VTI-208 Study Group

DOI

10.1002/lt.24986

Journal Title

Liver Transplantation

First Page

380

Last Page

393

Document Type

Article

Publication Date

March 2018

Department

Medicine

Keywords

Australia, Cell Line, Tumor, Extracorporeal Circulation, Hepatitis, Alcoholic, Hepatoblastoma, Intention to Treat Analysis, Kaplan-Meier Estimate, Liver Neoplasms, Prospective Studies, Risk Factors, Severity of Illness Index, Time Factors, Treatment Outcome, United Kingdom, United States

Disciplines

Medicine and Health Sciences

Abstract

Severe alcoholic hepatitis (sAH) is associated with a poor prognosis. There is no proven effective treatment for sAH, which is why early transplantation has been increasingly discussed. Hepatoblastoma-derived C3A cells express anti-inflammatory proteins and growth factors and were tested in an extracorporeal cellular therapy (ELAD) study to establish their effect on survival for subjects with sAH. Adults with sAH, bilirubin >/=8 mg/dL, Maddrey's discriminant function >/= 32, and Model for End-Stage Liver Disease (MELD) score

Comments

Please see the work for the complete list of authors.

Recommended Citation

Thompson, J., Jones, N., Al-Khafaji, A., Malik, S., Reich, D., Munoz, S., MacNicholas, R., Hassanein, T., Teperman, L., Wolf, D., & VTI-208 Study Group. (2018). Extracorporeal Cellular Therapy (ELAD) in Severe Alcoholic Hepatitis: A Multinational, Prospective, Controlled, Randomized Trial. Liver Transplantation, 24 (3), 380-393. https://doi.org/10.1002/lt.24986